| 000 | 01845nam a22004817a 4500 | ||
|---|---|---|---|
| 999 |
_c14032 _d14031 |
||
| 003 | OSt | ||
| 005 | 20231103135707.0 | ||
| 008 | 210615s2018 mou |||| fb|| 001 0 eng d | ||
| 020 | _a9780323297400 | ||
| 040 | _cQCPL | ||
| 082 | _a615.58 | ||
| 100 | 1 |
_aGahart, Betty L. _eauthor |
|
| 245 | 1 | 0 |
_aGahart's 2018 intravenous medications _b: a handbook for nurses and health professionals _c/ Betty L. Gahart, Adrienne R. Nazareno, Meghan Q. Ortega |
| 250 | _aThirty-fourth edition | ||
| 264 | 1 |
_aSt. Louis, Missouri : _bElsevier, _c[2018] |
|
| 300 | _axxii, 1416 pages | ||
| 336 |
_2rdacontent _atext |
||
| 337 |
_2rdamedia _aunmediated |
||
| 338 |
_2rdacarrier _avolume |
||
| 500 | _aIncludes index. | ||
| 505 | 0 | _aGeneral dilution charts | |
| 505 | 0 | _aEvolve website information | |
| 505 | 0 | _aHow to use this book | |
| 505 | 0 | _aPreface | |
| 505 | 0 | _aFormat and content of intravenous medications | |
| 505 | 0 | _aKey to abbreviations | |
| 505 | 0 | _aImportant IV therapy facts | |
| 505 | 0 | _aResources | |
| 505 | 0 | _aIV drugs | |
| 505 | 0 | _aAppendix A. Recommendations for the safe use and handling of cytotoxic drugs | |
| 505 | 0 | _aAppendix B. FDA pregnancy categories | |
| 505 | 0 | _aAppendix C. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) | |
| 505 | 0 | _aAppendix D. Information for patients receiving immunosuppressive agents | |
| 505 | 0 | _aAppendix E. Recently approved drugs | |
| 505 | 0 | _aIndex | |
| 505 | 0 | _aSolution compatibility chart | |
| 650 |
_aIntravenous therapy _vHandbooks, manuals, etc. |
||
| 650 | _aInjections, Intravenous | ||
| 650 | _aInfusions, Intravenous | ||
| 700 | 1 |
_aNazareno, Adrienne R. _eauthor |
|
| 700 | 1 |
_aOrtega, Meghan Q. _eauthor |
|
| 942 |
_2ddc _cBOOK |
||